Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Dulaglutide Monotherapy vs Placebo and Liraglutide in Type 2 Diabetes
jRCT2080221754Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Started Apr 2012; status: recruiting.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221754.